Successful Nucleoside Analog and Corticosteroid Therapy for Chronic Inflammatory Demyelinating Polyneuropathy in a Patient With Hepatitis B Virus Liver Cirrhosis

Eka Surya Nugraha, MD1, Ian Huang, MD2, Rudi Supriyadi, MD, MSc, PhD2, Dolvy Girawan, MD1, and Muhammad Begawan Bestari, MD, MHS, PhD, FASGE, FACP1

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
2Department of Internal Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia

ABSTRACT
Here, we describe the case of a 44-year-old man with chronic hepatitis B virus (HBV) infection, who was admitted with progressive muscle weakness and paresthesia in all extremities. He showed slight icterus. Positive HBV e-antigen test, significant HBV-deoxyribonucleic acid load, hypoalbuminemia, hyperbilirubinemia, mild ascites, and demyelinating peripheral axonal lesions in both sensory and motor nerves led to the diagnosis of Child-Pugh class B HBV cirrhosis with chronic inflammatory demyelinating polyneuropathy. Oral lamivudine, intravenous steroids, calcium, and vitamin D therapy led to a significant recovery of muscle strength within 6 weeks and a gradual return to normal after 24 weeks.

INTRODUCTION
Although hepatitis B virus (HBV) mainly affects hepatocytes, extrahepatic manifestations arise in approximately 20% of infected patients.1,2 These manifestations mostly involve the effects of immune complexes in vascular, renal, dermatologic, arthritic, and neurologic tissues.2–4 Of these, neurologic manifestations affect nearly 5% of patients with chronic HBV. Peripheral neuropathy is the most common neurologic manifestation of HBV, followed by acute inflammatory demyelinating polyneuropathy.3 By contrast, chronic inflammatory demyelinating polyneuropathy (CIDP) is rarely reported as an extrahepatic manifestation of HBV. Here, we report a chronic HBV patient with Child-Pugh B cirrhosis and quadriplegia due to CIDP. The latter condition gradually resolved after treatment with lamivudine and methylprednisolone.

CASE REPORT
A 44-year-old man with a 3-month history of progressive bilateral muscle weakness and paresthesia in his extremities was referred from a rural hospital to our center. Initially, he felt tingling sensations in both hands and feet, which worsened over time until he was unable to move his hands and limbs. Finally, he became almost totally bedridden with irritating sensations in his distal bilateral extremities. He had no history of head or back trauma.

On physical examination, his consciousness was fully alert and his other vital signs were normal. He was slightly anemic and mildly icteric. A neurological examination revealed hyporeflexia in all 4 limbs, with Medical Research Council muscle power grade of 3/5 in the upper limbs and 1/5 in the lower limbs. Hypesthesia was noted in all extremities, but pathological reflexes were absent. Laboratory examinations yielded the following data: hemoglobin, 8.5 gr/dL; platelets, 116,000/mm3; aspartate aminotransferase, 51 U/L; alanine aminotransferase, 56 U/L; total bilirubin, 1.2 mg/dL; prothrombin time, 14.3 seconds with an international normalized ratio of 1.3; albumin, 2.6 gr/dL; total protein, 7.0 gr/dL; and creatinine, 0.59 mg/dL. His electrolyte levels were normal. Repeated viral testing yielded positive results for the HBV soluble antigen (HBsAg) and HBV e-antigen and an HBV-deoxyribonucleic acid (DNA) load of 1.65 × 10^5 IU/mL, as well as negative hepatitis C virus and human immunodeficiency virus test results. An abdominal ultrasound showed minimal ascites.
Nerve conduction studies revealed prolongation of the motor distal latency and F-wave latency, and a reduction of the motor conduction velocity, which suggested peripheral axonal demyelination of both the sensory and motoric nerves (Table 1). A cerebrospinal fluid (CSF) analysis revealed a total cell count of 7 lymphocytes/mm³ and a protein concentration of 135 mg/dL. Serum protein electrophoresis revealed the presence of polyclonal gamma-globulinemia. Brain magnetic resonance imaging (MRI) revealed a lacunar infarction. The patient refused to undergo a biopsy.

Based on these observations, the patient was diagnosed with Child-Pugh class B HBV liver cirrhosis, CIDP, and anemia of chronic disease. Treatment was initiated with once-daily oral lamivudine (100 mg) and intravenous methylprednisolone (125 mg) for 3 days, followed by once-daily oral methylprednisolone (16 mg), an albumin infusion, calcium, and vitamin D supplementation. His muscle strength gradually improved, and he achieved a power grade of 2/5 in the lower-limb muscles after 4 weeks of treatment. At the 6-week follow-up, his lower-limb power grade had increased to 3/5 and he was able to sit independently. Finally, at the 24-week follow-up, he had achieved a grade of 5/5 in all 4 limbs and was able to walk. His HBV-DNA load at that time was $3.29 \times 10^2$ IU/mL. The result of the HBV-DNA test repeated at 48 weeks of lamivudine therapy was undetected.

### DISCUSSION

CIDP is an acquired peripheral neuropathy caused by damage to the peripheral nerve myelin and subsequent inflammatory demyelination. The condition is characterized by the occurrence of progressive symmetrical paralysis of both the proximal and distal muscles for more than 2 months. Very few cases of CIDP associated with HBV have been reported; only 5 cases have been reported to date (Table 2). Ours is the first report of a full recovery from CIDP in a patient with HBV and decompensated cirrhosis. However, we did not perform the HBV genotype test; the previous cases did not reveal it as well.

### Table 1. Results of nerve conduction studies of the right extremities

| Sensory                        | Latency (ms) | Amplitude (mV) | Velocity (m/s) |
|-------------------------------|--------------|----------------|----------------|
| Median                        | NR b         | N/A            | N/A            |
| Ulnar                         | NR b         | N/A            | N/A            |
| Peroneal/sural                | NR b         | N/A            | N/A            |
| Motor                         | Latency (ms) | Amplitude (mV) | Velocity (m/s) | F-waves |
| Median                        | 8.8 b        | 0.8 b          | 28 b           | NR b    |
| Ulnar                         | 3.5 b        | 1.3 b          | 47             | NR b    |
| Tibial                        | 11 b         | 0.2 b          | 39 b           | NR b    |
| Peroneal/sural                | 22.2 b       | 0.1 b          | 21 b           | NR b    |

N/A, not applicable; NR, no response.

b Abnormal values.

a Normal values for sensory/motor nerve conduction studies: latency <3.7/<3.1 ms, amplitude >8.0/>5.5 mV, and velocity >38/>45 m/s.

### Table 2. Baseline characteristics of HBV-related chronic inflammation demyelinating polynuepathy

| Case 1 7,8 | Case 2 13 | Case 3 12 | Case 4 14 | Case 5 15 |
|-----------|-----------|-----------|-----------|-----------|
| Age (yr)  | 60        | 60        | 39        | 44        | 57        |
| Sex       | Female    | Male      | Male      | Male      | Male      |
| Etiology  | HBV       | HBV       | HBV       | HBV       | HBV       |
| Cirrhosis | Compensated| Compensated| No        | No        | No        |
| HCV       | Hantavirus |           |           |           |           |
| HBV-DNA (IU/mL) | N/A | N/A | $8.5 \times 10^6$ | N/A | N/A |
| Therapy   | N/A       | IVIG      | IVIG      | Prednisolone | IVIG |
| Tenofovir | Azathioprine | Entecavir | Methylprednisolone | |
| Outcome   | N/A       | Improved | Improved | Improved | Improved |
| Follow-up (wk) | N/A | 4      | 24        | 32        | 52        |

HBV, hepatitis B virus; HCV, hepatitis C virus; IVIG, intravenous immunoglobulin; N/A, not applicable.
Although the exact pathogenic mechanism by which HBV causes CIDP remains unknown, several hypotheses have been proposed. Potentially, cytotoxic T cells might target and damage both HBsAg immune complexes and the myelin sheath.5,6 Other mechanisms involve direct HBV-mediated myelin damage and progressive polyneuropathy because of the deposition of HBsAg immune complexes in the vasa nervorum.7,8 In our case, CSF cytology immunofluorescence was not performed owing to the lack of the facility; consequently, the HBsAg immune complexes were unidentified.

Our CIDP diagnosis was based on the clinical, electrodiagnostic, and CSF analysis criteria.5,8 Specifically, our patient had a chronic onset of progressive, symmetric, proximal-to-distal, and bilateral muscle weakness with sensory abnormalities persisting for more than 2 months, met 3 of the 4 electrodiagnostic criteria, and exhibited an increased CSF protein concentration. Serum protein electrophoresis and MRI were conducted to exclude other differential diagnoses, including type I cryoglobulin-associated vasculitic neuropathy, multifocal motor neuropathy, and the polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome.5,10,11 However, type II or III mixed cryoglobulin was not excluded because the cryoglobulin and complement level examination could not be performed in our laboratory. Moreover, the MRI findings did not correlate with the symmetrical muscle weakness.

The patient was administered short-term intravenous and oral corticosteroid therapy and nucleoside analog (NA) treatment, which yielded a gradual recovery after 4 weeks of treatment. Despite high resistance, lamivudine was the favorable NA owing to wide availability and affordability. Based on the consensus of our hospital, lamivudine was preferred for HBV decompensated cirrhosis because tenofovir and entecavir were unaffordable by a majority of our patients. After 24 weeks of NA treatment, his motor functions had recovered and he was able to walk. Aktas et al similarly observed an improvement in muscle strength after 3 months of tenofovir administration in a patient with HBV-related CIDP. The mechanism was the NA reduced nerve tissue expression to HBsAg.15 Our cases and other cases therefore demonstrate that a combination of prompt NA and immunosuppressive drug therapy can effectively relieve the manifestations of CIDP, even in patients with advanced liver cirrhosis.

Acknowledgements: The authors would like to acknowledge Siti Aminah Sobada for providing neurologic care for the patient in this case.

Financial disclosure: None to report.

Previous presentation: This case was presented at the Asian Pacific Association for the Study of the Liver; March 4-8, 2020, Bali, Indonesia.

Informed consent was obtained for this case report.

Received April 20, 2020; Accepted September 4, 2020

REFERENCES

1. Yuen M-F, Chen D-S, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4(1):1–20.
2. Kappus MR, Sterling RK. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterol Hepatol (N Y). 2013;9(2):123–6.
3. Stübgen JP. Neuromuscular disorders associated with hepatitis B virus infection. J Clin Neuromuscular Dis. 2011;13(1):26–37.
4. Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am. 2009;35(1):125–37.
5. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–56.
6. Dyck PJ, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018;93(6):777–93.
7. Inoue A, Tsukada N, Koh CS, Yanagisawa N. Chronic relapsing demyelinating polyneuropathy associated with hepatitis B infection. Neurology. 1987;37(10):1663.
8. Tsukada N, Koh CS, Inoue A, Yanagisawa N. Demyelinating neuropathy associated with hepatitis B virus infection. Detection of immune complexes composed of hepatitis B virus surface antigen. J Neurol Sci. 1987;77(2–3):203–16.
9. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24(3):311–24.
10. Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. Eur J Neurol. 2010;17(3):356–63.
11. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55(1):4–13.
12. Aktas B, Baygıt S, Yılmaz B, Aktürk T, Nazlıgül Y. Dramatic improvement of chronic inflammatory demyelinating polyneuropathy through tenofovir treatment in a patient infected with hepatitis B virus. J Neuroimmune Pharmacol. 2015;10(2):191–2.
13. Ersoz G, Tekin F, Bademkiran F. Chronic inflammatory demyelinating polyneuropathy in an HCV-related cirrhotic patient with acute hepatitis B superinfection. Eur J Intern Med. 2007;18(3):257.
14. Lim JY, Lim Y-H, Choi E-H. Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. Medicine (Baltimore). 2016;95(49):e5580.
15. Lupescu I-C, Dulamea AO. Predominant upper limb chronic inflammatory demyelinating polyneuropathy associated with HBV infection. Maedica (Buchar). 2017;12(4):286–8.

DISCLOSURES

Author contributions: EK Nugraha and I. Huang wrote the manuscript and reviewed the literature. R. Supriyadi and D. Girawan revised the manuscript for intellectual content. MB Bestari approved the final manuscript and is the article guarantor.

Copyright: © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.